PuSH - Publication Server of Helmholtz Zentrum München: The expression profiles of lncRNAs are associated with neoadjuvant chemotherapy resistance in locally advanced, luminal B-type breast cancer.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

González-Woge, M.* ; Contreras-Espinosa, L.* ; García-Gordillo, J.A.* ; Aguilar-Villanueva, S.* ; Bargallo-Rocha, E.* ; Cabrera-Galeana, P.* ; Vasquez-Mata, T.* ; Cervantes-López, X.* ; Vargas-Lías, D.S.* ; Montiel-Manríquez, R.* ; Bautista-Hinojosa, L.* ; Rebollar-Vega, R.* ; Castro-Hernández, C.* ; Álvarez-Gómez, R.M.* ; De La Rosa Velázquez, I.A. ; Díaz-Chávez, J.* ; Jiménez-Trejo, F.* ; Arriaga-Canon, C.* ; Herrera, L.A.*

The expression profiles of lncRNAs are associated with neoadjuvant chemotherapy resistance in locally advanced, luminal B-type breast cancer.

Int. J. Mol. Sci. 25:8077 (2024)

Publ. Version/Full Text

DOI

PMC

	Open Access Gold

Abstract
Metrics
Extra information

lncRNAs are noncoding transcripts with tissue and cancer specificity. Particularly, in breast cancer, lncRNAs exhibit subtype-specific expression; they are particularly upregulated in luminal tumors. However, no gene signature-based laboratory tests have been developed for luminal breast cancer identification or the differential diagnosis of luminal tumors, since no luminal A- or B-specific genes have been identified. Particularly, luminal B patients are of clinical interest, since they have the most variable response to neoadjuvant treatment; thus, it is necessary to develop diagnostic and predictive biomarkers for these patients to optimize treatment decision-making and improve treatment quality. In this study, we analyzed the lncRNA expression profiles of breast cancer cell lines and patient tumor samples from RNA-Seq data to identify an lncRNA signature specific for luminal phenotypes. We identified an lncRNA signature consisting of LINC01016, GATA3-AS1, MAPT-IT1, and DSCAM-AS1 that exhibits luminal subtype-specific expression; among these lncRNAs, GATA3-AS1 is associated with the presence of residual disease (Wilcoxon test, p < 0.05), which is related to neoadjuvant chemotherapy resistance in luminal B breast cancer patients. Furthermore, analysis of GATA3-AS1 expression using RNA in situ hybridization (RNA ISH) demonstrated that this lncRNA is detectable in histological slides. Similar to estrogen receptors and Ki67, both commonly detected biomarkers, GATA3-AS1 proves to be a suitable predictive biomarker for clinical application in breast cancer laboratory tests.

Impact Factor

Scopus SNIP

Altmetric

4.900

0.000